YURIA-PHARM IS A UKRAINIAN PHARMACEUTICAL GROUP WITH A GLOBAL OUTLOOK
















THE ONLY ONE OF THE TOP-5 UKRAINIAN PHARMACEUTICAL COMPANIES BUILT FROM THE GROUND UP

1990 FOUNDED

1998 YURIA-PHARM LTD. MANUFACTURING ESTABLISHED IN CHERKASY





KEY BUSINESS DIRECTIONS

R&D

Manufacturing

Marketing

Distribution





YURIA-PHARM IN UKRAINE

3,3% MARKET SHARE

#3 HOSPITAL DISTRIBUTOR IN UKRAINE (7.8% MARKET SHARE)**

13,4% MARKET SHARE IN PARENTERAL MEDICINES *

#3

BY TURNOVER*

Source:

^{*}Proxima, 2021, retail + hospital, published 02.22


^{**} Proxima, Q1-Q4 2021, hospital, published 02.22





OPERATIONS IN

25% **EXPORT SHARE**







REGISTERED REPRESENTATIVE OFFICES

UZBEKISTAN

KAZAKHSTAN

TAJIKISTAN

KIRGHISIA

MOLDOVA

VIETNAM



600+

REGISTRATION CERTIFICATES

20+

NEW PRODUCTS EVERY YEAR





INTENSIVE & RECOVERY









SBU Intensive & Recovery is the largest revenue contributor, accounting for over 70% of the corporation's turnover. This strategic business unit is actively engaged in:

- developing world-class original product concepts aimed at solving current clinical challenges
- enhancing existing products with new clinical strategies and indications, including "Wave Breaker" and "Long Haul"





INFECTION & RESPIRATORY











The Anti-infection & Respiratory SBU is a dynamic business unit with the highest number of new launches. The INCURE association, which is part of this SBU, works on anti-TB drugs with the aim of addressing the major social issue that is severe tuberculosis.





PAINLESS & ONCOLOGY













Antipain & Oncology strategic business unit is focused on more than just development and introduction of innovative products – but also on creating comprehensive approaches revolving around the combination of products with unique services involving personalization, drug combination, service, and information.





MEDICAL DEVICES & NEPHROLOGY





The MD & Nephrology strategic business unit includes such key portfolios as:

- hyaluronic acid products, a portfolio with high international potential and quick scalability
- functional waters (ReO), a portfolio with a high growth dynamic and the option to expand existing distribution channels
- peritoneal dialysis products for renal failure patients



PRODUCTION IN UKRAINE

41 PRODUCTION LINES

25,000 m² PRODUCTION AREA

290 mil
TOTAL PRODUCT UNITS / YEAR

• 204, 000, 000
PHARMACEUTICAL
PRODUCTS

• **86.000.000**MEDICAL DEVICES





PERSONALIZED PHARMACEUTICALS UKRAINE

953

RECIPES

1076

ORDERS FROM HEALTHCARE FACILITIES

143, 914

PRIMARY PACKAGES

 $1800 \, \text{M}^2$

UNIQUE PRODUCTION SPACE

93

EXTEMPORAL PREPARATIONS





PRODUCTION IN ITALY (DIACO)

7 PRODUCTION LINES

33 mil
PRODUCT UNITS / YEAR

3,000 m² PRODUCTION AREA

- **30,000,000** INFUSIA
- **2, 200, 000** COSMETIC
- **440,000**MEDICAL DEVICE





DISTRIBUTION

 $\begin{array}{c} 33,000 \\ m^2 \end{array}$

COMBINED WAREHOUSE SPACE IN UKRAINE

• 9200 m²

MTC MEDICAL CENTER LTD.
PHARMACY WAREHOUSES

- 21202 m²
 FINISHED PRODUCT WAREHOUSES
- 2300 m²
 YURIA-PHARM LTD.
 PHARMACY WAREHOUSE



2800

like-minded associates

